APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Diabetes Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GLP-1 Diabetes Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025195 pages

Choose your research edition.

Industry ResearchGLP-1 Diabetes Treatment Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Diabetes Treatment Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal GLP-1 Diabetes Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Diabetes Treatment Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Diabetes Treatment Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global GLP-1 Diabetes Treatment Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Diabetes Treatment Drugs include Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Sanofi, Page Biopharmaceuticals, Novo Nordisk, Eli Lilly, Jiangsu Hausen Pharmaceuticals Group Co., Ltd., Huadong Medicine and Ganli Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Diabetes Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Diabetes Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Diabetes Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Diabetes Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Diabetes Treatment Drugs Segment by Company

Tonghua Dongbao

Shanghai Renhui Biopharmaceuticals Co., Ltd.

Sanofi

Page Biopharmaceuticals

Novo Nordisk

Eli Lilly

Jiangsu Hausen Pharmaceuticals Group Co., Ltd.

Huadong Medicine

Ganli Pharmaceuticals

AstraZeneca

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Hanmi Pharmaceutical Co

GlaxoSmithKline (GSK)

Boehringer Ingelheim

GLP-1 Diabetes Treatment Drugs Segment by Type

Exenatide

Dulaglutide

Laglutide

Others

GLP-1 Diabetes Treatment Drugs Segment by Application

Online Pharmacy

Hospital

Clinic

GLP-1 Diabetes Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Diabetes Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Diabetes Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Diabetes Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Diabetes Treatment Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Diabetes Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GLP-1 Diabetes Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GLP-1 Diabetes Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Diabetes Treatment Drugs Industry Trends Table 2. GLP-1 Diabetes Treatment Drugs Industry Drivers Table 3. GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges Table 4. GLP-1 Diabetes Treatment Drugs Industry Restraints Table 5. Global GLP-1 Diabetes Treatment Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GLP-1 Diabetes Treatment Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Manufacturers Table 9. Global GLP-1 Diabetes Treatment Drugs Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global GLP-1 Diabetes Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GLP-1 Diabetes Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GLP-1 Diabetes Treatment Drugs Manufacturers, Product Type & Application Table 13. Global GLP-1 Diabetes Treatment Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Diabetes Treatment Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Exenatide Table 17. Major Manufacturers of Dulaglutide Table 18. Major Manufacturers of Laglutide Table 19. Major Manufacturers of Others Table 20. Global GLP-1 Diabetes Treatment Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 22. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2027-2032) & (k units) Table 23. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Type (2021-2026) Table 24. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Type (2027-2032) Table 25. Global GLP-1 Diabetes Treatment Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global GLP-1 Diabetes Treatment Drugs Revenue by Type (2021-2026) & (k units) Table 27. Global GLP-1 Diabetes Treatment Drugs Revenue by Type (2027-2032) & (k units) Table 28. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Type (2021-2026) Table 29. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Online Pharmacy Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Global GLP-1 Diabetes Treatment Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 35. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2027-2032) & (k units) Table 36. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Application (2021-2026) Table 37. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Application (2027-2032) Table 38. Global GLP-1 Diabetes Treatment Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global GLP-1 Diabetes Treatment Drugs Revenue by Application (2021-2026) & (k units) Table 40. Global GLP-1 Diabetes Treatment Drugs Revenue by Application (2027-2032) & (k units) Table 41. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Application (2021-2026) Table 42. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Application (2027-2032) Table 43. Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2026) & (k units) Table 45. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Region (2021-2026) Table 46. Global GLP-1 Diabetes Treatment Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global GLP-1 Diabetes Treatment Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 50. North America GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032) & (k units) Table 51. Europe GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 53. Europe GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032) & (k units) Table 60. Global GLP-1 Diabetes Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global GLP-1 Diabetes Treatment Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global GLP-1 Diabetes Treatment Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Region (2021-2026) Table 64. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Region (2027-2032) Table 65. Tonghua Dongbao Company Information Table 66. Tonghua Dongbao Business Overview Table 67. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio Table 69. Tonghua Dongbao Recent Development Table 70. Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information Table 71. Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview Table 72. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 74. Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio Table 79. Sanofi Recent Development Table 80. Page Biopharmaceuticals Company Information Table 81. Page Biopharmaceuticals Business Overview Table 82. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 84. Page Biopharmaceuticals Recent Development Table 85. Novo Nordisk Company Information Table 86. Novo Nordisk Business Overview Table 87. Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio Table 89. Novo Nordisk Recent Development Table 90. Eli Lilly Company Information Table 91. Eli Lilly Business Overview Table 92. Eli Lilly GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio Table 94. Eli Lilly Recent Development Table 95. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information Table 96. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview Table 97. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 99. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Development Table 100. Huadong Medicine Company Information Table 101. Huadong Medicine Business Overview Table 102. Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio Table 104. Huadong Medicine Recent Development Table 105. Ganli Pharmaceuticals Company Information Table 106. Ganli Pharmaceuticals Business Overview Table 107. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 109. Ganli Pharmaceuticals Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Teva Pharmaceutical Industries Ltd Company Information Table 116. Teva Pharmaceutical Industries Ltd Business Overview Table 117. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio Table 119. Teva Pharmaceutical Industries Ltd Recent Development Table 120. Pfizer Inc Company Information Table 121. Pfizer Inc Business Overview Table 122. Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio Table 124. Pfizer Inc Recent Development Table 125. Hanmi Pharmaceutical Co Company Information Table 126. Hanmi Pharmaceutical Co Business Overview Table 127. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio Table 129. Hanmi Pharmaceutical Co Recent Development Table 130. GlaxoSmithKline (GSK) Company Information Table 131. GlaxoSmithKline (GSK) Business Overview Table 132. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio Table 134. GlaxoSmithKline (GSK) Recent Development Table 135. Boehringer Ingelheim Company Information Table 136. Boehringer Ingelheim Business Overview Table 137. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio Table 139. Boehringer Ingelheim Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. GLP-1 Diabetes Treatment Drugs Distributors List Table 143. GLP-1 Diabetes Treatment Drugs Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. GLP-1 Diabetes Treatment Drugs Product Image Figure 2. Global GLP-1 Diabetes Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Diabetes Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Diabetes Treatment Drugs Sales (2021-2032) & (k units) Figure 5. Global GLP-1 Diabetes Treatment Drugs Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 GLP-1 Diabetes Treatment Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Exenatide Image Figure 9. Dulaglutide Image Figure 10. Laglutide Image Figure 11. Others Image Figure 12. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global GLP-1 Diabetes Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Type (2021-2032) Figure 15. Global GLP-1 Diabetes Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Type (2021-2032) Figure 18. Online Pharmacy Image Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global GLP-1 Diabetes Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Application (2021-2032) Figure 24. Global GLP-1 Diabetes Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. France GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2032) Figure 41. China GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. India GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile GLP-1 Diabetes Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global GLP-1 Diabetes Treatment Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America GLP-1 Diabetes Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe GLP-1 Diabetes Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific GLP-1 Diabetes Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. GLP-1 Diabetes Treatment Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. GLP-1 Diabetes Treatment Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatide
  • Dulaglutide
  • Laglutide
  • Others
Applications
  • Online Pharmacy
  • Hospital
  • Clinic
Companies covered
  • Tonghua Dongbao
  • Shanghai Renhui Biopharmaceuticals Co., Ltd.
  • Sanofi
  • Page Biopharmaceuticals
  • Novo Nordisk
  • Eli Lilly
  • Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  • Huadong Medicine
  • Ganli Pharmaceuticals
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Hanmi Pharmaceutical Co
  • GlaxoSmithKline (GSK)
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GLP-1 Diabetes Treatment Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GLP-1 Diabetes Treatment Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GLP-1 Diabetes Treatment Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GLP-1 Diabetes Treatment Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GLP-1 Diabetes Treatment Drugs Market Dynamics
  1. 2.1 GLP-1 Diabetes Treatment Drugs Industry Trends
  2. 2.2 GLP-1 Diabetes Treatment Drugs Industry Drivers
  3. 2.3 GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Diabetes Treatment Drugs Industry Restraints
3 GLP-1 Diabetes Treatment Drugs Market by Manufacturers
  1. 3.1 Global GLP-1 Diabetes Treatment Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GLP-1 Diabetes Treatment Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Diabetes Treatment Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Diabetes Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Diabetes Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GLP-1 Diabetes Treatment Drugs Manufacturers, Product Type & Application
  7. 3.7 Global GLP-1 Diabetes Treatment Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Diabetes Treatment Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Diabetes Treatment Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Diabetes Treatment Drugs Tier 1, Tier 2, and Tier 3
4 GLP-1 Diabetes Treatment Drugs Market by Type
  1. 4.1 GLP-1 Diabetes Treatment Drugs Type Introduction
  2. 4.1.1 Exenatide
  3. 4.1.2 Dulaglutide
  4. 4.1.3 Laglutide
  5. 4.1.4 Others
  6. 4.2 Global GLP-1 Diabetes Treatment Drugs Sales by Type
  7. 4.2.1 Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global GLP-1 Diabetes Treatment Drugs Revenue by Type
  11. 4.3.1 Global GLP-1 Diabetes Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global GLP-1 Diabetes Treatment Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Type (2021-2032)
5 GLP-1 Diabetes Treatment Drugs Market by Application
  1. 5.1 GLP-1 Diabetes Treatment Drugs Application Introduction
  2. 5.1.1 Online Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global GLP-1 Diabetes Treatment Drugs Sales by Application
  6. 5.2.1 Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Diabetes Treatment Drugs Revenue by Application
  10. 5.3.1 Global GLP-1 Diabetes Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Diabetes Treatment Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Application (2021-2032)
6 Global GLP-1 Diabetes Treatment Drugs Sales by Region
  1. 6.1 Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global GLP-1 Diabetes Treatment Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GLP-1 Diabetes Treatment Drugs Revenue by Region
  1. 7.1 Global GLP-1 Diabetes Treatment Drugs Revenue by Region
  2. 7.1.1 Global GLP-1 Diabetes Treatment Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GLP-1 Diabetes Treatment Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global GLP-1 Diabetes Treatment Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GLP-1 Diabetes Treatment Drugs Revenue (2021-2032)
  8. 7.2.2 North America GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GLP-1 Diabetes Treatment Drugs Revenue (2021-2032)
  11. 7.3.2 Europe GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GLP-1 Diabetes Treatment Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GLP-1 Diabetes Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao
  2. 8.1.1 Tonghua Dongbao Company Information
  3. 8.1.2 Tonghua Dongbao Business Overview
  4. 8.1.3 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio
  6. 8.1.5 Tonghua Dongbao Recent Developments
  7. 8.2 Shanghai Renhui Biopharmaceuticals Co., Ltd.
  8. 8.2.1 Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information
  9. 8.2.2 Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview
  10. 8.2.3 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  12. 8.2.5 Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Page Biopharmaceuticals
  20. 8.4.1 Page Biopharmaceuticals Company Information
  21. 8.4.2 Page Biopharmaceuticals Business Overview
  22. 8.4.3 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  24. 8.4.5 Page Biopharmaceuticals Recent Developments
  25. 8.5 Novo Nordisk
  26. 8.5.1 Novo Nordisk Company Information
  27. 8.5.2 Novo Nordisk Business Overview
  28. 8.5.3 Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio
  30. 8.5.5 Novo Nordisk Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  38. 8.7.1 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information
  39. 8.7.2 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview
  40. 8.7.3 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  42. 8.7.5 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Developments
  43. 8.8 Huadong Medicine
  44. 8.8.1 Huadong Medicine Company Information
  45. 8.8.2 Huadong Medicine Business Overview
  46. 8.8.3 Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio
  48. 8.8.5 Huadong Medicine Recent Developments
  49. 8.9 Ganli Pharmaceuticals
  50. 8.9.1 Ganli Pharmaceuticals Company Information
  51. 8.9.2 Ganli Pharmaceuticals Business Overview
  52. 8.9.3 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  54. 8.9.5 Ganli Pharmaceuticals Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Teva Pharmaceutical Industries Ltd
  62. 8.11.1 Teva Pharmaceutical Industries Ltd Company Information
  63. 8.11.2 Teva Pharmaceutical Industries Ltd Business Overview
  64. 8.11.3 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio
  66. 8.11.5 Teva Pharmaceutical Industries Ltd Recent Developments
  67. 8.12 Pfizer Inc
  68. 8.12.1 Pfizer Inc Company Information
  69. 8.12.2 Pfizer Inc Business Overview
  70. 8.12.3 Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio
  72. 8.12.5 Pfizer Inc Recent Developments
  73. 8.13 Hanmi Pharmaceutical Co
  74. 8.13.1 Hanmi Pharmaceutical Co Company Information
  75. 8.13.2 Hanmi Pharmaceutical Co Business Overview
  76. 8.13.3 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio
  78. 8.13.5 Hanmi Pharmaceutical Co Recent Developments
  79. 8.14 GlaxoSmithKline (GSK)
  80. 8.14.1 GlaxoSmithKline (GSK) Company Information
  81. 8.14.2 GlaxoSmithKline (GSK) Business Overview
  82. 8.14.3 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio
  84. 8.14.5 GlaxoSmithKline (GSK) Recent Developments
  85. 8.15 Boehringer Ingelheim
  86. 8.15.1 Boehringer Ingelheim Company Information
  87. 8.15.2 Boehringer Ingelheim Business Overview
  88. 8.15.3 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio
  90. 8.15.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Diabetes Treatment Drugs Value Chain Analysis
  2. 9.1.1 GLP-1 Diabetes Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Diabetes Treatment Drugs Production Mode & Process
  6. 9.2 GLP-1 Diabetes Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Diabetes Treatment Drugs Distributors
  9. 9.2.3 GLP-1 Diabetes Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst